When was Morphogen-IX founded?

Morphogen-IX was founded in 2015 and raised its 1st funding round 1 year after it was founded.

Where is Morphogen-IX located?

Morphogen-IX is headquartered in Cambridge, United Kingdom.

Which legal entities is Morphogen-IX associated with?

Morphogen-IX is associated with MORPHOGEN-IX LIMITED.

How many employees does Morphogen-IX have?

As of Jul 31, 2020, the latest employee count at Morphogen-IX is 1.

Is Morphogen-IX a funded company?

Morphogen-IX is a funded company, having raised a total of $25.3M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 18, 2016.

When was the latest funding round of Morphogen-IX?

Morphogen-IX's latest funding was a $***** Series B round on Dec 18, 2018, with participation from 3 investors. Its primary sector is Cardiac and Vascular Disorders. Globally, the Cardiac and Vascular Disorders sector has seen $1.11B in funding in 2026 to date.

Where does Morphogen-IX rank among its competitors?

Morphogen-IX ranks 6th amongst 11 active competitors, of which 7 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Retension Pharmaceuticals, which secured $15M in Apr, 2025.

Who are the top competitors of Morphogen-IX?

Morphogen-IX's top competitors include Mineralys Therapeutics, Retension Pharmaceuticals and Zymedi. Among them, Retension Pharmaceuticals secured the most recent funding round in April, 2025.

Morphogen-IX - 2026 Company Profile, Team, Funding, Competitors & Financials

Morphogen-IX is a series B company based in Cambridge (United Kingdom), founded in 2015. It operates as a Provider of therapeutics for pulmonary arterial hypertension (PAH). Morphogen-IX has raised $25.3M in funding from Medicxi. The company has 11 active competitors, including 7 funded and 1 that has exited. Its top competitors include companies like Mineralys Therapeutics, Retension Pharmaceuticals and Zymedi.

Company Details

Morphogen-IX is developing a new treatment for pulmonary arterial hypertension (PAH). Its leading candidate can directly target the major pathway implicated in human genetic studies (BMP9 and BMP10) which are small molecule-based receptors.

Key Metrics

Founded Year

2015

Location

Cambridge, United Kingdom

Stage

Series B

Total Funding

$25.3M in 2 rounds

Latest Funding Round

Series B, Dec 18, 2018, $*****

Investors

Medicxi & 3 more

Ranked

6^th among 11 active competitors

Employee Count

1 as on Jul 31, 2020

Similar Companies

Mineralys Therapeutics & 12 more

View Morphogen-IX's full profile

Morphogen-IX is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MORPHOGEN-IX LIMITED CIN: 09686738 , United Kingdom, Active	Jul 14, 2015	-	1 (As on Jul 31, 2020)

Morphogen-IX has raised a total funding of $25.3M over 2 rounds. Its first funding round was on Jan 18, 2016. Its latest funding round was a Series B round on Dec 18, 2018 for $*****. 3 investors participated in its latest round. Morphogen-IX has 4 institutional investors.

Here is the list of recent funding rounds of Morphogen-IX:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 18, 2018	2992170	Series B	6969927	2020252	4082451	2261254
Jan 18, 2016	2931434	Seed	2185015	7174481	6959261	Index Ventures & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Morphogen-IX's funding rounds and investors

Morphogen-IX's Board of Directors

Morphogen-IX's board has 5 active members. Dr Grainger David John, Dr Tansley Robert Giles, Nicholas Professor Morrell, Dr Dobrée Anne Michelle and Dr Johnson Kevin Stuart are independent board members.

Here is the list of Morphogen-IX's board of directors:

Name	Type	Representing	Status	Duration
Dr Grainger David John	Independent board member	-	Current	8y 10m
xaprkqw	Independent board member	-	Current	2y 8m
nrum{zf	Independent board member	-	Current	6y 6m
xplnzya	Independent board member	-	Current	7y 9m
jihycrh	Independent board member	-	Current	3y 8m
ixdtmwa	Independent board member	-	Past	8y 1m

Morphogen-IX's employee count trend

Morphogen-IX has 1 employees as of Jul 20. The total employee count is the same as what it was in Jul 19. Here is Morphogen-IX's employee count trend over the years:

Uncover Morphogen-IX's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Morphogen-IX include Mineralys Therapeutics, Retension Pharmaceuticals and Zymedi. Here is the list of Top 10 competitors of Morphogen-IX, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Mineralys Therapeutics 2020, Radnor (United States), Public	Developer of therapy for the treatment of hypertension	$158M	Samsara BioCapital, HBM Healthcare Investments ... & 15 others	61/100
2nd	Retension Pharmaceuticals 2023, Falls Church (United States), Series B	Developer of treatments for hypertension and cardiovascular diseases	$25.4M	Collage Venture Partners	51/100
3rd	Zymedi 2019, Incheon (South Korea), Series A	Developer of therapeutics for multiple diseases	$29.5M	Company K Partners, KVIC & 6 others	40/100
4th	Autotelic Bio 2015, South Korea, Series B	Developer of therapeutics for cancer treatment	$18.2M	UTC Investment, DT&Investment & 12 others	39/100
5th	Retension Pharmaceuticals 2023, Mclean (United States), Series B	Developer of pharmaceutical treatments for hypertension and cardiovascular diseases	$10.1M	-	32/100
6th	Morphogen-IX 2015, Cambridge (United Kingdom), Series B	Provider of therapeutics for pulmonary arterial hypertension (PAH)	$25.3M	Index Ventures, Cambridge Enterprise & 2 others	27/100
7th	Avirmax 2019, Hayward (United States), Funding Raised	Developer of rAAV mediated gene therapies	-	3E Bioventures Capital	27/100
8th	Linnet Biopharmaceuticals 2010, New York City (United States), Seed	Developer of drugs for cardiac health	$25K	-	24/100
9th	PEARKO Therapeutics 2013, Edmonton (Canada), Unfunded	Develope of pharmacological therapies for cardiovascular diseases	-	-	23/100
10th	Ridge Therapeutics 2017, Lake Bluff (United States), Deadpooled	Reformulation and redevelopment of existing drugs	-	-	23/100